Takeda and Norgine terminate obesity drug deal

13 July 2018

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) and Netherlands-based Norgine have agreed to terminate the license and development agreement for the development, manufacture and sale in Japan of Oblean (cetilistat), a drug for the treatment of obesity, as of October 13, 2018.

The announcement this morning saw Takeda’s shares gain 1.73% to 4,691 yen.

"I would like to express my appreciation to patients and healthcare providers who made efforts for us to receive the Japanese New Drug Application Approval," said Masato Iwasaki, president of the Japan Pharma Business unit and director of Takeda, adding:" Takeda will continue to contribute to patients in Japan with its existing range of drugs for lifestyle-related diseases."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK